



# discoCHO™ Transient Expression Platform

Discovery in CHO-K1

Robust Titers

Rapid Timelines

discoCHO™



# discoCHO™:


## Bridging Discovery & Development

Therapeutic biologics, including antibodies, cytokines, enzymes, and more, are usually produced in high-expressing transient HEK or CHO-S cells during the discovery phase and then transferred to stable CHO-K1 cells for scale-up and manufacturing. This switch in the host cell line between discovery and development often results in poor predictability of cell line productivity and Critical Quality Attributes (CGA) of the biologic. ATUM addresses this challenge with discoCHO, a CHO-K1-based transient platform that seamlessly integrates discovery hits into ATUM's CHO-K1-based stable miCHO-GS platform, reducing manufacturing risks.


- Benefits:**
- Rapid timelines: sequence to protein in under 4 weeks
  - Scalable: from mg to gram scale
  - Simple fee-for-service model
  - Integrated CHO-K1-based platforms: discoCHO transient to miCHO stable

### What is the discoCHO Platform?

A transient expression platform using ATUM's CHO-K1-based host for production of mg to grams of product. The platform gives you the ability to predict critical quality attributes before initiating clinical programs and avoiding unpleasant surprises during manufacturing.




## Robust Titers Across Volumes:



discoCHO titers are robust across various discovery scales

## Representative Product Quality



discoCHO transient is representative of miCHO stable

ATUM's technology platforms: discoCHO™ | Leap-In Transposase® | miCHO® stable

Contact us to access our technology platforms as fee-for-service:

+1 650 853 8347

+1 877 DNA TOGO


info@atum.bio



## Your Life Science Partner

37950 Central Court  
Newark, CA 94560  
U.S.A.

+1 877 DNA TOGO  
+1 650 853 8347  
info@atum.bio  
www.atum.bio



research. create. break through.